全国政协委员吴德沛：让创新药离患者更近

Group 1 - The core issue in the healthcare sector is the accessibility of innovative drugs, as many patients cannot afford them despite their availability [1][2] - A systematic investigation was conducted by a national political advisor focusing on the accessibility of innovative drugs, involving discussions with various stakeholders including medical institutions, pharmaceutical companies, and insurance agencies [2] - A proposal was made to establish a mechanism that integrates basic medical insurance, commercial insurance, and social assistance to improve the payment pathways for high-value innovative drugs [2] Group 2 - The release of the "Commercial Health Insurance Innovative Drug Directory (2025)" is seen as a significant policy advancement that provides additional payment channels for innovative drugs, bringing them closer to patients [2] - The focus has shifted towards leveraging big data to enhance medical services and precision diagnosis, emphasizing the importance of data utilization in benefiting patients [2][3] - Continuous follow-up and advocacy are essential in the process of integrating innovative drugs into a multi-tiered healthcare insurance system, reflecting a commitment to addressing urgent healthcare challenges [3]